A recent medical study investigated the potential usefulness of mucin 21 (MUC21), as a novel, negative diagnostic marker for purpose of differentiating epithelioid mesothelioma from lung adenocarcinoma. In order to analyze the expression of MUC21 by immunohistochemistry, 70 epithelioid mesothelioma and 70 lung adenocarcinoma cases were examined. Ultimately, the medical researchers found that for differentiating epithelioid mesothelioma from lung adenocarcinoma, MUC21 could be used as an additional, novel, negative immunohistochemical marker. This study was first published online by the medical journal Histopathology in October 2018.[Read Abstract for medical journal article]
Mesothelioma, Asbestos, and Legal Compensation: Basic Facts
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.